Nadofaragene firadenovec in high-risk Bacillus Calmette Guérin unresponsive non-muscle invasive bladder cancer: a profile of its use

被引:1
作者
Nie, Tina [1 ]
机构
[1] Springer Nat, Private Bag 65901, Auckland 0754, New Zealand
关键词
CARCINOMA IN-SITU; EXPRESSION; CYSTECTOMY; THERAPY; SYN3; MICE;
D O I
10.1007/s40267-024-01045-0
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Nadofaragene firadenovec (Adstiladrin (R)) is an important bladder-sparing option in the treatment of patients with high-risk Bacillus Calmette Guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC). Radical cystectomy is the recommended treatment in these patients; however, many are ineligible or refuse to undergo this major procedure and other options are limited. Intravesical nadofaragene firadenovec, a replication-deficient adenovirus-based gene therapy that causes localized expression of interferon (IFN) alpha 2b in the bladder, is approved in the USA for the treatment of adults with high-risk BCG-unresponsive NMIBC with carcinoma in situ (CIS) with or without papillary tumors. In a phase 3 clinical trial including patients with BCG-unresponsive NMIBC with CIS, nadofaragene firadenovec was efficacious in producing complete responses. Nadofaragene firadenovec had an acceptable safety profile and was generally well tolerated, with a small number of patients experiencing a grade 3 treatment-related adverse event and none experiencing a grade 4 or 5 drug-related adverse event. Cystectomy should be considered in patients who do not have a complete response to nadofaragene firadenovec or who have recurrence of CIS. Bacillus Calmette Guerin (BCG) is used in patients with high-risk non-muscle invasive bladder cancer (NMIBC) to reduce recurrence and prevent disease progression; however, a large proportion of patients develop BCG-unresponsive NMIBC. Radical cystectomy to remove the bladder is potentially curative in these patients, but many are unable or unwilling to undergo this major surgery. Nadofaragene firadenovec (Adstiladrin (R)) is a gene therapy administered into the bladder that causes localized expression of interferon (IFN) alpha 2b, which promotes an anti-tumor immune response. It is approved in the USA for the treatment of adults with high-risk BCG-unresponsive NMIBC with carcinoma in situ (CIS) with or without papillary tumors. In a pivotal clinical trial in patients with BCG-unresponsive NMIBC with CIS, nadofaragene firadenovec effectively produced complete responses (i.e. no detectable signs of bladder cancer). Nadofaragene firadenovec had an acceptable safety profile and was generally well tolerated, with most treatment-related adverse events being mild or moderate in severity. Thus, current evidence suggests that nadofaragene firadenovec is an important bladder-sparing treatment option in patients with high-risk BCG-unresponsive NMIBC with CIS.
引用
收藏
页码:1 / 8
页数:8
相关论文
共 50 条
  • [31] Bacillus Calmette-Guerin for the Treatment of Non-muscle Invasive Bladder Cancer: History and Current Status
    Liu, Gang
    Li, Bingheng
    Xu, Ziyang
    Wang, Jie
    Ma, Sai
    Kan, Yi
    Mao, Lijun
    DISCOVERY MEDICINE, 2022, 33 (169) : 85 - 92
  • [32] Low-dose Bacillus Calmette-Guerin versus full-dose for intermediate and high-risk of non-muscle invasive bladder cancer: a Markov model
    Wang, Zongren
    Xiao, Han
    Wei, Guangyan
    Zhang, Ning
    Wei, Mengchao
    Chen, Zebin
    Peng, Zhenwei
    Peng, Sui
    Qiu, Shaopeng
    Li, Heping
    Long, Jianting
    BMC CANCER, 2018, 18
  • [33] Immune phenotype of peripheral blood mononuclear cells in patients with high-risk non-muscle invasive bladder cancer
    Audenet, Francois
    Farkas, Adam M.
    Anastos, Harry
    Galsky, Matthew D.
    Bhardwaj, Nina
    Sfakianos, John P.
    WORLD JOURNAL OF UROLOGY, 2018, 36 (11) : 1741 - 1748
  • [34] Unmet Need in Non-muscle-invasive Bladder Cancer Failing Bacillus Calmette-Guérin Therapy: A Systematic Review and Costeffectiveness Analyses from the International Bladder Cancer Group
    D'Andrea, David
    Mostafid, Hugh
    Gontero, Paolo
    Shariat, Shahrokh
    Kamat, Ashish
    Masson-Lecomte, Alexandra
    Burger, Maximilian
    Roupret, Morgan
    EUROPEAN UROLOGY ONCOLOGY, 2025, 8 (01): : 216 - 229
  • [35] Predictive biomarkers of response to bacillus Calmette-Guerin immunotherapy and bacillus Calmette-Guerin failure for non-muscle invasive bladder cancer
    Wang, Ziting
    So, Wei Zheng
    Loh, Kep Yong
    Lim, Yew Koon
    Mahendran, Ratha
    Wu, Qing Hui
    Chiong, Edmund
    INTERNATIONAL JOURNAL OF UROLOGY, 2022, 29 (08) : 807 - 815
  • [36] BCG unresponsive non-muscle invasive bladder cancer: The beginning of a new era?
    Guerrero-Ramos, F.
    ACTAS UROLOGICAS ESPANOLAS, 2023, 47 (06): : 329 - 331
  • [37] Second transurethral resection and prognosis of high-grade non-muscle invasive bladder cancer in patients not receiving bacillus Calmette-Guerin
    Angulo, J. C.
    Palou, J.
    Garcia-Tello, A.
    de Fata, F. R.
    Rodriguez, O.
    Villavicencio, H.
    ACTAS UROLOGICAS ESPANOLAS, 2014, 38 (03): : 164 - 171
  • [38] Comparison of Bacillus Calmette-Guérin Maintenance Therapy with Monthly Instillations and the Southwest Oncology Group Protocol in the Treatment of Non-muscle-invasive Bladder Cancer
    Nurminen, Pertti
    Nummi, Antti
    Kesti, Olli
    Ettala, Otto
    Hoegerman, Mikael
    Jarvinen, Riikka
    Sairanen, Jukka
    Kaipia, Antti
    Bostrom, Peter J.
    EUROPEAN UROLOGY FOCUS, 2023, 9 (06): : 1000 - 1007
  • [39] Intravesical Thalidomide boosts bacillus Calmette-Guerin (BCG) in non-muscle invasive bladder cancer treatment
    Passos, Gabriela R.
    Camargo, Juliana A.
    Ferrari, Karen L.
    Saad, Mario J. A.
    de Mattos, Amilcar C.
    Reis, Leonardo O.
    MEDICAL ONCOLOGY, 2018, 35 (01)
  • [40] International Bladder Cancer Group Consensus Statement on Clinical Trial Design for Patients with Bacillus Calmette-Guerin-exposed High-risk Non-muscle-invasive Bladder Cancer
    Roumiguie, Mathieu
    Kamat, Ashish M.
    Bivalacqua, Trinity J.
    Lerner, Seth P.
    Kassouf, Wassim
    Bohle, Andreas
    Brausi, Maurizio
    Buckley, Roger
    Persad, Raj
    Colombel, Marc
    Lamm, Donald
    Palou-Redorta, Juan
    Soloway, Mark
    Brothers, Ken
    Steinberg, Gary
    Lotan, Yair
    Sylvester, Richard
    Witjes, J. Alfred
    Black, Peter C.
    EUROPEAN UROLOGY, 2022, 82 (01) : 34 - 46